Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06016634
PHASE2
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Sponsor: University of California, Davis
View on ClinicalTrials.gov
Summary
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Official title: A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-02-09
Completion Date
2027-12-31
Last Updated
2026-01-30
Healthy Volunteers
No
Interventions
DRUG
Alendronate Sodium
Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
Locations (1)
UC Davis Comprehensive Cancer Center
Sacramento, California, United States